Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of AbbVie (NYSE:ABBV) rose 1.5% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share were up 21.90% over the past year to $2.95, which beat the estimate of $2.83.
Revenue of $13,010,000,000 rose by 50.95% year over year, which beat the estimate of $12,760,000,000.
Outlook
The upcoming fiscal year's EPS expected to be between $12.37 and $12.57.
Details Of The Call
Date: Apr 30, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/5j8dgnqr
Recent Stock Performance
Company's 52-week high was at $113.41
Company's 52-week low was at $79.11
Price action over last quarter: Up 3.65%
Company Overview
AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!